Abbott Confirms FDA Advisory Panel to Review XIENCE(TM) V Drug Eluting Stent on November 29

Medical Letter on the CDC & FDA via NewsEdge Corporation :

2007 NOV 25 - (NewsRx.com) -- Abbott (NYSE:ABT) announced that the U.S. Food and Drug Administration (FDA) has confirmed a Circulatory Systems Devices Advisory Panel meeting on Nov. 29, 2007, to review the company's Premarket Approval (PMA) submission for the XIENCE(TM) V Everolimus Eluting Coronary Stent System (see also Heart Attack).
Abbott filed its PMA for XIENCE V with the FDA on June 1, 2007. The company anticipates that it will launch XIENCE V in the U.S. in the first half of 2008, pending FDA approval.

read the full article: http://www.devicelink.com/newsedge/